



Press Release

Stockholm, 20 April 2007

Håkan Åström appointed as new chairman of the board of Affibody

Affibody Holding AB, a biotech company that has developed a late-stage pipeline of oncology products for molecular imaging and targeted therapy, announces that the Annual General Meeting on 20 April 2007 appointed Håkan Åström as new chairman of the board and Ursula Ney as a new board member.

The board of directors of Affibody Holding AB comprises, besides Håkan Åström and Ursula Ney, also Karl Swartling, Björn Odlander and Mathias Uhlén.

For further information, please contact:

Ulf Boberg, Chief Executive Officer
+46 8 598 838 10, ulf.boberg@affibody.com

Erika Johnson, Chief Financial Officer
+46 8 598 838 16, erika.johnson@affibody.com

About Affibody

Affibody is a biotech company that has developed a late-stage pipeline of oncology products for molecular imaging and targeted therapy. Affibody's mission is to provide the medical community with previously not available information for timely cancer diagnosis and appropriate individualized treatment regimes.

The key components of Affibody's proprietary technology platform are unique and highly specific affinity ligands: Affibody[®] molecules. These small robust protein molecules are easy to produce and can be designed to bind to any target protein. The Affibody molecules are ideal for molecular imaging. Importantly, the same Affibody[®] molecule can, with a cytotoxic payload, be used for targeted therapeutics. Affibody's vision is to be a leading player in the emerging field of molecular imaging and targeted therapeutics.

The company's lead product for molecular imaging is targeting HER2, a key receptor on e.g. certain breast cancer tumors, and is expected to be commercially launched in 2009. Affibody[®] molecules specific for other oncology targets are in development and will provide a steady stream of new molecular imaging products and subsequently, targeted therapeutic products. Affibody also develops Affibody[®] molecules within commercial collaborations for various applications.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute in Stockholm. Investors in Affibody Holding AB include HealthCap, Schroder Ventures Life Sciences and Investor. Affibody is based in Stockholm, Sweden and has 50 employees. Further information is found on: www.affibody.com



Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Affibody's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.